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ABSTRACT
OX40 (CD134), an activation-induced costimulatory molecule, is mainly expressed on CD41T cells. Several re-
ports, including previous reports from our laboratory, suggest that OX40-mediated signaling plays an important
role in the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplan-
tation (Allo HSCT). Here, we show that peripheral blood CD41OX401 T cells are a unique cell subset as they
possess the homing receptors of lymph nodes, and some of them have an exceptional capacity to produce high
levels of interleukin-2 (IL-2) upon the stimulation through T cell receptors. Stimulation with IL-7 acts selec-
tively onCD41OX401T cells not only to induce antigen-independent growth but also to increase the frequency
of cells with IL-2-producing potential. Simultaneous, but not sequential, ligation of theT cell receptor andOX40
induces CD41OX401T cells to produce far more IL-2, which causes them to proliferate abundantly and differ-
entiate readily into Th1- or Th2-biased effector memory T cells, especially in Allo HSCT recipients. Although
not all the CD41OX401 T cells had IL-2-producing capacity, Allo HSCT recipients with chronic GVHD
(cGVHD) had a significantly higher frequency of IL-2-producing OX401 cells in their peripheral blood CD41
T cell subset than Allo HSCT recipients without cGVHD. Collectively, CD41OX401T cells with IL-2-produc-
ing potential are expected to be privileged for growth and differentiation in lymph nodes upon antigen
presentation, suggesting that they might be involved in the process of inducing or maintaining cGVHD.
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Chronic graft-versus-host disease (cGVHD) re-
mains a serious complication that affects long-term
survivors of allogeneic hematopoietic stem cell trans-
plantation (Allo HSCT). It is not only the leading
cause of nonrelapse mortality (NRM), it is also associ-
ated with decreased quality of life [1]. To prevent and
treat GVHD, immunosuppressive agents such as calci-
neurin inhibitors are generally used, which increases
the risk of developing opportunistic infections. It has
been shown that GVHD is initiated by donor-derived
CD41 and CD81 T cells that recognize a subset of
host antigens [2,3]. Indeed, it has been shown that ex
vivo depletion of the T cells in the graft effectively re-268duces the incidence and severity of acute GVHD
(aGVHD) [4,5]. Unfortunately, this technique is also
associated with increased incidences of graft rejection,
relapses, and infectious complications, which prevents
it from being widely used. Another technique to specif-
ically deplete donor-derived alloreactive T cells that is
currently being developed involves stimulating the
graft with recipient cells in vitro and then depleting
the activated T cells with monoclonal antibodies
(mAb) [6-8]. However, such depletion-based tech-
niques would probably fail to prevent cGVHD be-
cause the alloreactive T cells that cause cGVHD are
believed to be derived from hematopoietic stem cells
(HSC) in the graft rather than already being mature
T cells [9-12]. A better way to prevent and treat
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cells are directly responsible for this disease; these cells
could then be readily detected in the blood and specif-
ically depleted within the host.
OX40 (CD134) is a member of the tumor necrosis
factor (TNF) receptor superfamily [13], and is an acti-
vation-induced antigen that is predominantly ex-
pressed on CD41 T cells [14]. The ligand for OX40
(OX40L) is mainly expressed on activated antigen-pre-
senting cells (APCs) such as dendritic cells and B cells
[15-17]. OX40 signaling acts as an important costimu-
latory signal, as it augments interleukin 2 (IL-2) pro-
duction [18,19], prolongs cell survival by
upregulating Bcl-2 and Bcl-xL expression [20], induces
the clonal expansion of naı¨veCD41Tcells [19,21], and
generates memory T cells by promoting the survival of
effectorT cells [19,22,23].OX40-mediated signaling is
also indispensable for expanding memory T cells in
secondary immune responses and prolonging their sur-
vival [24]. A large body of evidence suggests that
OX40-mediated signaling plays a pivotal role in the de-
velopment of several immune-mediated conditions
such as experimental autoimmune encephalomyelitis
[16,25], collagen-induced arthritis [26], allergic lung
inflammation [24,27], inflammatory bowel disease
[28], and GVHD [29,30]. Because the in vivo blockade
ofOX40-mediated signals ameliorates these diseases in
murine models, it is possible that targeting OX40 may
also be useful for treating human diseases [14].
Buenafe et al [31] reported that the antigen-spe-
cific T cells in the spinal cord of Lewis rats displaying
experimental autoimmune encephalomyelitis are fre-
quently CD41OX401 T cells. Tittle et al [32] showed
that CD41OX401 T cells are the alloreactive T cells
in a murine GVHD model. In addition, we previously
showed that the occurrence of cGVHD correlates
positively with the frequency of peripheral blood
CD41OX401 T cells [33]. Consequently, we specu-
lated that the circulating CD41OX401 T cell subset
of Allo HSCT recipients contains alloreactive T cells
that are involved in the process of inducing and main-
taining cGVHD. To further understand the role
CD41OX401 T cells play in the development of
cGVHD, we here isolated the CD41OX401 T cells
from Allo HSCT recipients and healthy volunteers
(HVs) and assessed their characteristics.
SUBJECTS, MATERIALS, AND METHODS
Subjects
Peripheral blood samples were obtained from 13
HVs and 43 Allo HSCT recipients who had under-
gone transplantation at least 100 days previously.
Each subject gave written informed consent. Allo
HSCT recipients were required to be in complete do-
nor chimerism as well as in complete remission at the
time of sampling. The clinical characteristics of theAllo HSCT recipients are summarized in Table 1.
Standard conditioning for patients with hematologic
malignancies consisted of 12 Gy total-body irradiation
(TBI) and cyclophosphamide (Cy; 120 mg/kg), 12 Gy
TBI and melphalan (Mel; 140 mg/m2), or busulfan
(Bu/Cy; 16 mg/kg) and Cy (120 mg/kg). Patients
with aplastic anemia (AA) received 200 mg/kg Cy
and antithymocyte-globulin (ATG), and a patient
with adrenoleukodystrophy was treated with Bu (8
mg/kg), Cy (120 mg/kg), and 7.5Gy total lymphoid ir-
radiation [34]. Reduced-intensity conditioning (RIC)
was performed using 2-4 Gy TBI, fludarabine (Flu;
125 mg/m2), and either Bu (8 mg/kg) or Mel (80-140
mg/m2). The presence of cGVHD in Allo HSCT re-
cipients was defined as the presence of active symp-
toms, for which immunosuppressive therapy was
required [1,35]. In other words, patients defined as
positive for cGVHD included patients with extensive
cGVHD and patients with limited cGVHD, which
manifests itself as significant hepatic dysfunction
(value of Alkaline Phosphatase greater than twice the
normal upper limit). All studies involving these blood
samples were approved by the institutional review
board of Kyoto University.
Table 1. Patient Characteristics
Characteristics Data
No. male/no. female 20/23
Median age, years (range) 52 (25-74)
Diagnosis, no. (%)
Acute lymphoblastic leukemia 2 (5)
Acute myelogenous leukemia 12 (28)
Myelodysplastic syndrome 7 (16)
CML/MPD 7 (16)
Adult T cell Leukemia 1 (2)
Lymphoma 8 (19)
Myeloma 3 (7)
Aplastic anemia 2 (5)
Adreno-leukodystrophy 1 (2)
Donor type, no. (%)
Matched related 19 (44)
Matched unrelated 16 (37)
Mismatched related 5 (12)
Mismatched unrelated 3 (7)
Conditioning regimen, no. (%)
Standard 24 (56)
Reduced intensity 20 (44)
Stem cell source, no. (%)
Bone marrow 27 (62)
Peripheral blood 14 (33)
Cord blood 2 (5)
cGVHD, no. (%)
Yes 23 (53)
No 20 (47)
Immunosuppression at the time of
analysis, no. (%)
29 (67)
Median time after Allo HSCT for analysis,
mo (range)
12 (4-149)
CML/MPD indicates chronic myelogenous leukemia/myeloprolif-
erative disorder; cGVHD, chronic graft-versus-host disease;
Allo HSCT, allogeneic hematopoietic stem cell transplantation.
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An anti-OX40 mAb (131, mouse IgG1) was estab-
lished in our laboratory [36]. It was used either as a pu-
rified protein or it was biotinylated by using EZ-Link
Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL). For
flow cytometric analysis, cells were incubated with ap-
propriate concentrations of fluorescein isothiocyanate
(FITC)-, phycoerythrin (PE)-, or allophycocyanin
(APC)-conjugated mAbs in the dark at 4C for 20min-
utes. The cells were then washed twice and analyzed by
flow cytometry on FACSCalibur (BD Biosciences, San
Jose, CA) with CELLQuest software (BD Biosci-
ences). PE-conjugated anti-OX40 (PE-anti-OX40),
APC-anti-CD45RA, FITC- and PE-anti-interferon
g (IFN-g), PE-anti-interleukin 4 (IL-4), and Alexa
647-anti-IL7Ra (CD127) were purchased from BD
Pharmingen (San Diego, CA). FITC-anti-CD45RO,
FITC-anti-CD25, PE-anti-IL-2, FITC-anti-IL-4,
and all the isotype-matched control mAbs were ob-
tained from eBioscience (San Diego, CA). FITC-
anti-CD62L and FITC-anti-CCR7 were obtained
from Beckman Coulter (Fullerton, CA) and R&D sys-
tems (Minneapolis, MN), respectively. Intracellular
Foxp3 staining was performed by using the PE-conju-
gated anti-human Foxp3 staining set (PCH101, eBio-
science) according to the manufacturer’s instructions.
Staining of cytoplasmic phosphorylated STAT5 was
performed by using Alexa 488-anti-phospho-STAT5
(clone 47, BD Biosciences) according to the manufac-
turer’s instructions. To detect apoptotic cells and
dead cells, the cells were stained with 1 mg/mL propi-
dium iodide (PI, Sigma-Aldrich, St. Louis, MO) for 15
minutes at room temperature. For cell proliferation
analysis, the cells were labeled for 10 minutes at
room temperature with carboxyfluorescein succini-
midyl ester (CFSE, Molecular Probes, Eugene, OR)
at a final concentration of 5 mM in phosphate-buffered
saline (PBS) containing 0.1% bovine serum albumin
(BSA, Sigma-Aldrich).
T Cell Isolation and Sorting
Peripheral blood mononuclear cells (PBMC) were
isolated fromHVs and Allo HSCT recipients by using
Ficoll-Hypaque Plus (Amersham Pharmacia Biotech,
Piscataway, NJ) density gradient centrifugation. The
CD41 T cells were isolated with CD4 Multisort Kit
(Miltenyi Biotec Bergisch Gladbach, Germany) and
their purity exceeded 97%. CD41T cells were stained
with biotinylated anti-OX40 mAb followed by APC-
streptavidin (eBioscience) and sorted into OX401
and OX40- fractions by FACSAria (BD Biosciences)
with FACSDiVA 4.1 software (BD Biosciences). In
some experiments, the cells were also stained with
PE-anti-CD45RA (BD Pharmingen) and sorted into
OX401 memory (CD45RA2OX401) and OX402memory (CD45RA2OX402) cells. The sorted T cell
subsets were more than 90% pure.
Flow Cytometric Analysis of Intracellular
Cytokines
For intracellular cytokine staining, cells were sus-
pended in culture medium consisting of RPMI 1640
(Invitrogen, Carlsbad, CA), 10% fetal calf serum
(FCS, Hyclone, Logan, UT) and 1% penicillin-strep-
tomycin-glutamine mixture (Invitrogen) and stimu-
lated for 6 or 16 hours in plates coated with
anti-CD3 mAb (OKT3, 10 mg/mL) with or without
anti-OX40 mAb (131, 10 mg/mL) in the presence of
2 mg/mL soluble anti-CD28 mAb (H046, mouse
IgG1, agonistic antibody established in our laboratory;
T. Hori, unpublished data) (aCD3/28 or aCD3/28/
OX40 stimulation). Brefeldin A (BFA, Sigma-Aldrich)
was added at a concentration of 10 mg/mL for the last 4
hours. In some experiments, cells were stimulated with
PMA (50 ng/mL, Sigma-Aldrich) and ionomycin (500
ng/mL, Sigma-Aldrich) for 4 hours in the presence of
BFA (PMA/Iono stimulation). After stimulation, the
cells were washed twice, surface stained with the ap-
propriate mAbs, and fixed with 2% formaldehyde
(Wako Pure Chemical Industries, Osaka, Japan) di-
luted in PBS. The cells were then permeabilized with
0.2% saponin (Sigma-Aldrich)-containing buffer and
intracellular cytokine levels were measured by using
the relevant mAbs.
Assessment of Cytokine Release by ELISA
To detect IL-2 in the culture supernatants, cells at
a concentration of 5  105/mL were stimulated for 24
hours with aCD3/28 or aCD3/28/OX40 as described
above. The IL-2 levels in the medium were measured
by enzyme-linked immunosorbent assay (ELISA) us-
ing a rabbit anti-human IL-2 polyclonal Ab (Pierce
Biotechnology, Rockford, IL), a biotinylated-anti-hu-
man IL-2 mAb (BG5, mouse IgG1, Pierce Biotechnol-
ogy), and a recombinant human IL-2 standard (Pierce
Biotechnology) according to the manufacturer’s
instructions.
T Cell Culture and Stimulation
For experiments using interleukin 7 (IL-7), cells
were suspended in culture medium in the presence or
absence of 1 ng/mL IL-7 (Peprotech, Rocky Hill,
NJ) for 5 days. For polyclonal stimulation and expan-
sion, isolated CD41 T cell subsets were suspended in
culture medium at a concentration of 5  105/mL
and stimulated for 12 hours with aCD3/28 or
aCD3/28/OX40 in 48- or 96-well plates. The
cells were then harvested, washed, and cultured for
4 days in culture medium. In some experiments, after
12 hours of stimulation followed by washing, the
cells were cultured in plates coated with anti-OX40
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4 days.
Statistical Analysis
Results are expressed as means 6 standard devia-
tion (SD). The statistical significance of differences
was determined by using a 2-sided paired t-test or Stu-
dent’s t-test. Differences with P\ .05 were considered
to be significant.
RESULTS
The CD41OX401 T Cell Subset Shares the
Characteristics of Central Memory T Cells
We first tested the frequency of OX40-expressing
peripheral blood CD41 T cells in Allo HSCT recipi-
ents and HVs by multicolor flowcytometry. Although
OX40 is an activation-induced antigen, we found it
was expressed on a considerable number of peripheral
blood CD41T cells from both groups. However, Allo
HSCT recipients showed higher frequencies of
OX401 cells (Figure 1A). Further analysis revealed
that nearly all of the CD41OX401 T cells belonged
to the CD45RO1 memory subset and most also ex-
pressed CCR7 and CD62L (Figure 1B and C), which
indicates that they are central memory T cells. There
were no significant differences in the CD41OX401
T cells from HVs and Allo HSCT recipients in terms
of their CD45RO, CCR7, and CD62L expression. As
CD41CD251 regulatory T cells are also reported to
express OX40 [37-41], we determined the intracellular
Foxp3 levels in the CD41CD251 T cells and
CD41OX401 T cells. Although a considerable pro-
portion of the CD41CD251 T cells were Foxp31,
fewer than 10% of the CD41OX401 T cells from
both Allo HSCT recipients and HVs were Foxp31
(Figure 1D). Recent reports indicated that regulatory
T cells have reduced expression of CD127 (IL-7R al-
pha chain, IL-7Ra) [42].We also found that themajor-
ity of CD41CD25high T cells were IL-7Ralow.
However, CD41OX401 T cells were almost all IL-
7Rahigh (Figure 1D). Collectively, CD41OX401 T
cells include a minor population of regulatory T cells.
To further characterize the CD41OX401 T cells,
CD41T cells that were freshly isolated fromHVs and
Allo HSCT recipients were sorted into OX401 and
OX402 fractions (Figure 2A), stimulated with
aCD3/28 for 6 hours, and then subjected to intracellu-
lar cytokine staining (Figure 2B and C). There were no
differences in the frequency of IL-2-producing cells in
the CD41 T cell population upon aCD3/28 stimula-
tion when CD41 T cells were isolated with magneti-
cally labeled anti-CD4 mAb or negatively selected to
enrich for CD41T cells (data not shown). In addition,
we confirmed that the binding of anti-OX40 mAb,
clone 131, to the cell surface was not enough to affect
the IL-2-producing capacity of the cells, because theaddition of soluble anti-OX40 mAb to CD41 T cells
did not alter the frequency of IL-2-producing cells
after subsequent aCD3/28 stimulation (data not
shown). There were marked differences between Allo
HSCT recipients and HVs in terms of the cytokine
profiles of their OX402 cells. Although there were
very few IL-2-, IFN-g-, or IL-4-producing cells in
the OX402 cells from HVs, a large proportion (over
30%) of the OX402 cells from Allo HSCT recipients
produced IFN-g; a small population of these IFN-g-
producing cells (about 5%-10%) also produced IL-2.
In contrast, about 10% of the OX401 cells from
both the Allo HSCT recipients and HVs produced
IL-2, whereas very few cells produced IFN-g or IL-
4. As we could not detect cells that produce IFN-g
and IL-4 simultaneously (data not shown), we defined
the cells that produce IL-2 but not IFN-g or IL-4 as
TIL-2 cells. The frequency of TIL-2 cells was calculated
as follows: (the frequency of all IL-2-producing cells) –
(the frequency of IFN-g- and IL-2-producing cells) –
(the frequency of IL-4- and IL-2-producing cells). As
shown in Figure 2C, TIL-2 cells were only detected
in the OX401 fraction of both Allo HSCT recipients
and HVs.
Signaling from IL-7R and Crosslinking of OX40
Robustly Augments IL-2 Production by OX401
Memory T Cells
As OX401 cells exclusively exist within the mem-
ory cell fraction, we next compared the characteristics
of OX401memory cells and OX402memory cells. To
this end, CD41 T cells of HVs were stained with PE-
anti-CD45RA and biotinylated-anti-OX40 Ab before
adding streptavidin-APC and sorting them into
CD45RA2OX401 T cells and CD45RA2OX402 T
cells. We regarded the former as OX401memory cells
and the latter as OX402 memory cells.
IL-7 is known to be critically involved in maintain-
ing memory CD41 T cell homeostasis through its
ability to induce antigen-independent proliferation in
the periphery [43,44]. We found that the addition of
IL-7 to culture medium sustained and augmented
OX40 expression on CD41 T cells (data not shown).
We then investigated the association between surface
expression of OX40 and its ability to produce IL-2.
First, freshly sorted OX401 memory cells were cul-
tured in growth medium unsupplemented with cyto-
kines. Five days later, the cells had lost OX40
expression as well as IL-2-producing capacity in re-
sponse to aCD3/28 stimulation (the left row of
Figure 3A). After sorting and CFSE-labeling,
OX401 memory cells from HVs were then cultured
for 5 days in the presence of IL-7. The cells showed en-
hanced expression of OX40 and an increased fre-
quency of IL-2-producing cells. Meanwhile, culture
of OX402 memory cells with IL-7 neither induced
the expression of OX40 nor enhanced the capacity of
272 T. Shindo et al.Figure 1.The CD41OX401T cell subset contains central memory T cells. (A-C) Peripheral blood CD41T cells of Allo HSCT recipients and
HVs were analyzed for OX40, CD45RO, CCR7, and CD62L expression. (A) The frequencies of OX40-positive cells in the CD41T cell subset
from 36 Allo HSCT recipients and 13 HVs are shown as means 6 SD. *P\ .01 (B) The dot plots shown are representative of 25 Allo HSCT
recipients. (C) The frequencies of CD45RO-, CCR7-, and CD62L-positive cells in theOX401T cell subset from 4 AlloHSCT-recipients and 3
HVs are shown as means 6 SD. (D) CD41 T cells from Allo HSCT recipients and HVs were analyzed for correlations in their expression of
CD25, OX40, intracellular Foxp3, and IL-7Ra. The dot plots shown are representative of 6 Allo HSCT recipients (upper) and 3 HVs (lower).these cells to produce IL-2 (the right row of
Figure 3A). Taken together, there seems to be a close
association between the expression of OX40 and IL-2-
producing capacity. In addition, a significant propor-
tion of OX401memory cells treated with IL-7 showed
a decreased CFSE staining intensity, indicating that
they had begun to proliferate. To determine whether
IL-7 differentially delivered signals downstream of
IL-7R, the phosphorylation status of cytoplasmic
STAT5 was analyzed. As shown in Figure 3B,
STAT5 was phosphorylated equally well in OX401memory cells and OX402 memory cells upon IL-7
stimulation.
As previously reported [18], crosslinking of OX40
in addition to aCD3/28 stimulation resulted in a re-
markable increase in the amount of IL-2 production
by OX401memory cells (Figure 4A). When we exam-
ined the IL-2 production of OX401memory cells at 2-
6 and 12-16 hours after stimulation, the costimulation
through OX40 increased the frequency of IL-2-pro-
ducing cells over time from 7% at 2-6 hours to about
13% at 12-16 hours (Figure 4B).
Many Advantages in Growth of CD41OX401 T Cells 273Figure 2.CD41OX401 T cells show an increased propensity to produce IL-2 in response to antigenic stimulation. (A) CD41T cells from Allo
HSCT recipients and HVs were sorted into OX401 and OX402 fractions. (B) Cytokine production by OX401 and OX402 cells stimulated
with aCD3/28. The data shown are representative of 10 Allo HSCT recipients (left) and 9 HVs (right). (C) The frequencies of cytokine-pro-
ducing OX401 and OX402 cells are shown as means6 SD. TIL-2 cells were defined as the cells that produce IL-2 but not IFN-g or IL-4. *P\
.01, #P\ .05.OX40-Mediated Signaling Enhances the Survival
and Proliferation of OX401 Memory T Cells
Having demonstrated that OX401 memory cells
produce massive amounts of IL-2 when the OX40-me-
diated signal is present during antigenic stimulation,
we next examined the effects of OX40-mediated sig-
naling on the survival and proliferation of OX401
memory cells. For this, sorted OX401 memory cells
from Allo HSCT recipients were labeled with CFSE,
stimulated with aCD3/28 or aCD3/28/OX40 for 12hours, washed, and then cultured for 4 days in growth
medium without exogenous cytokines. As a control,
OX402 memory cells were treated similarly. The in-
tensity of the CFSE signal was analyzed to determine
the degree to which the cells had proliferated, while
their positivity for propidium iodide was analyzed to
determine their susceptibility to apoptosis. The
OX402 memory cells of Allo HSCT recipients did
not proliferate and lost their viability during the course
of cell cultivation (the left row of Figure 5A and B).
274 T. Shindo et al.Figure 3. OX401 memory T cells have greater survival and proliferation potentials. (A) CD41 T cells from HVs were sorted into
CD45RA2OX401 T cells (OX401 memory T cells) and CD45RA2OX402 T cells (OX402 memory T cells). Then, the cells were labeled
with CFSE and cultured in the absence or presence of 1 ng/mL IL-7 for 5 days before measuring OX40 expression, division profile, and IL-
2-production upon aCD3/28 stimulation. The dot plots shown are representative of 3 independent experiments. (B) CD41 T cells of HVs
were incubated for 15 minutes in the absence or presence of 1 ng/mL IL-7 and analyzed for OX40 and cytoplasmic phosphorylated-STAT5
(pSTAT5). Data are representative of 3 HVs.In contrast, OX401 memory cells showed substantial
cell growth and high viability in response to aCD3/
28 stimulation (the middle row of Figure 5A and B).
When OX40 ligation was present during aCD3/28
stimulation, the OX401 memory cells showed explo-
sive proliferation without impairment of cell viability
(the right row of Figure 5A and B).
OX40 is transiently expressed upon TCR trigger-
ing, peaking at 48 hours and disappearing after 72 to
96 hours in vitro [19]. We also found that 12-hour
stimulation with aCD3/28 induces the expression of
OX40 on OX402 memory cells with similar kinetics.
We next evaluated the effect of delivering the OX40-
mediated signal after aCD3/28 stimulation
(Figure 5C). For this, OX401 memory and OX402
memory cells from HVs were labeled with CFSE,
and then stimulated with aCD3/28 or aCD3/28/
OX40 for 12 hours. After washing, the cells were cul-
tured in plates coated with mouse IgG1 (Figure 5C,
upper dot plots and histograms) or anti-OX40 Ab
(Figure 5C, lower dot plots and histograms) for an ad-
ditional 4 days. When the OX401 memory cells werestimulated with aCD3/28 before incubation with
anti-OX40 Ab, a marginal increase in the proportion
of CFSE-low and PI-negative cells was seen (the mid-
dle row of Figure 5C). As forOX402memory cells, de-
spite the acquisition of OX40, they neither showed
enhanced proliferation nor increased cell viability
when the OX40-mediated signal was subsequently
added (the left row of Figure 5C). Thus, for CD41
T cells to maintain their viability and expand effi-
ciently, antigenic and OX40-mediated signals must
be present simultaneously.
Effect of OX40-Mediated Signaling on
Differentiation into Effector Memory T Cells
As CD41OX401 T cells are central memory T
cells, we next investigated whether OX40-mediated
signaling promotes their differentiation into effector
memory T cells. For this, OX402 memory and
OX401 memory cells were stimulated for 12 hours
with aCD3/28 or aCD3/28/OX40, washed, cultured
in medium without exogenous cytokines for 4 days,
and then analyzed for their cytokine profiles. As shown
Many Advantages in Growth of CD41OX401 T Cells 275in the right row of Figure 6A, the majority of OX401
memory cells fromHVs given aCD3/28/OX40 stimu-
lation did not produce IFN-g or IL-4. In contrast, the
aCD3/28/OX40-stimulated OX401 memory cells
from Allo HSCT recipients showed substantial differ-
entiation into effector memoryT cells (the right row of
Figure 6B). Interestingly, the directions of polarization
differed between the patients: OX401 memory cells
from Case 1, a patient with refractory multiorgan
cGVHD,mainly differentiated into the Th1 direction,
whereas those from Case 2, a patient with pulmonary
cGVHD, differentiated mainly into Th2-type cells.
These results suggest that OX40-mediated signaling
induces OX401 memory T cells from Allo HSCT re-
cipients not only to proliferate, but also to differentiate
into effector memory T cells.
Allo HSCT Recipients with cGVHD Have Much
Higher Frequencies of IL-2-Producing OX401Cells
among CD41 T Cells Than Allo HSCT Recipients
without cGVHD
As for the detection of intracellular cytokines,
PMA/Iono stimulation has been widely used [45].
Figure 4. Crosslinking of OX40 enables OX401 memory T cells to
produce massive amounts of IL-2 for an extended time period. (A,B)
CD41 T cells fromHVs were sorted into CD45RA2OX401T cells
(OX401 memory T cells) and CD45RA2OX402 T cells (OX40-
memory T cells). (A) The cells were subjected to aCD3/28 or
aCD3/28/OX40 stimulation for 24 hours. The levels of IL-2 se-
creted into the culture supernatants were measured by ELISA and
are shown as means 6 SD. (B) OX401 memory T cells of HVs
were stimulated with aCD3/28 or aCD3/28/OX40 and their IL-2-
production 2-6 hours (upper) and 12-16 hours (lower) later was
analyzed. The data shown are representative of 3 independent exper-
iments.Compared with aCD3/28 stimulation, we could detect
cytokine-producing cells more frequently when CD41
T cells from Allo HSCT recipients and HVs were
stimulated with PMA/Iono. As shown in Figure 7A,
PMA/Iono stimulation of CD41 T cells resulted in
massive IL-2 production not only in OX401 cells but
also in OX402 cells, which was not observed upon
aCD3/28 stimulation. This suggests that PMA/Iono
stimulation could promote IL-2-production even in
cells that are not prepared for TCR-mediated signal-
ing. Notably, we found that the CD41OX401 T cells
were heterogeneous in their ability to produce IL-2 in
response to PMA/Iono stimulation. We then exam-
ined the frequency of OX401 cells capable of produc-
ing IL-2 in Allo HSCT recipients with (n 5 15) or
without (n 5 10) cGVHD. As BFA was continuously
present during the stimulation, there was no increase
in cell surface OX40 molecules during PMA/Iono
stimulation. Consequently, we not only examined
how OX40 expression on its own relates to cGVHD
(left panel of Figure 7B), we also examined the correla-
tion between the frequency of IL-21OX401 cells and
the occurrence of cGVHD (right panel of Figure 7B).
Higher frequencies of OX401 cells were observed on
average in the cGVHD patients, which is consistent
with our previous observations (P 5 .032) [33]. How-
ever, a closer correlation with cGVHD was detected
when we examined the frequency of IL-2-producing
OX401 cells (P 5 .007).
DISCUSSION
Since the concept of central memory and effector
memory T cells was proposed [46], the heterogeneity
of memory T cells has been an active area of research.
Although the origin of central memory and effector
memory T cells remains relatively poorly understood
[47], it is generally accepted that central memory T
cells produce IL-2, show high proliferative potential,
and differentiate into cytokine-producing effector cells
upon TCR triggering [48]. In this study, we found that
circulating CD41OX401 T cells show these charac-
teristics of central memory T cells, and they contain
the cells that produce a large amount of IL-2 in re-
sponse to aCD3/28 stimulation. Not only central
memory T cells but also naı¨ve and effector memory
T cells have been shown to express OX40 in vivo
[49,50]. However, we could not detect OX40 on any
circulating naı¨ve and effector memory CD41 T cells
from Allo HSCT recipients or HVs. Although it is un-
clear why there is preferential expression of OX40 on
central memory T cells in the circulating CD41 T
cell population, we speculate as follows: naı¨ve and cen-
tral memory CD41T cells that received activating sig-
nals in the lymphoid organs become effector cells or
OX401 ‘‘activated’’ central memory T cells depending
on the inflammatory status of the lymphoid tissues.
276 T. Shindo et al.Figure 5.The presence of OX40-mediated signaling during antigenic stimulation results in explosive cell growth. (A,B) OX401memory T cells
and OX402 memory T cells from Allo HSCT recipients were labeled with CFSE, stimulated with aCD3/28 or aCD3/28/OX40 for 12 hours,
washed, and cultured in growth medium for 4 days. (A) Upper dot plots show the PI-negative cells (viable cells) and lower histograms show the
division profile of each cell population. The data shown are representative of 3 experiments. (B) The proportions of viable cells and proliferating
cells are shown as means6 SD. *P\ .01 #P\ .02 (C) OX401memory T cells and OX402memory T cells fromHVs were labeled with CFSE,
stimulated with aCD3/28 or aCD3/28/OX40 for 12 hours, washed, and then cultured in plates coated with mouse IgG1 (upper dot plots and
histograms) or aOX40 Ab (lower dot plots and histograms) for 4 days. Dot plots show the PI staining and histograms show the division profile.
The data shown are representative of 3 experiments.Some of the latter cells return to the circulation as
OX401 central memory T cells. In contrast, effector
memory T cells that received antigenic stimulation
would not return into circulation because they become
effector cells and cannot survive long enough.Surprisingly, IL-7, a cytokine critically involved in
regulating the homeostasis of naı¨ve and memory
CD41 T cells, selectively upregulated the expression
of OX40, enhanced IL-2-producing potential, and
promoted antigen-independent proliferation in
Many Advantages in Growth of CD41OX401 T Cells 277Figure 6. CD41OX401 T cells from Allo HSCT recipients differentiate into Th1 or Th2 effector cells in response to aCD3/28/OX40 stim-
ulation. CFSE-labeled OX401 memory T cells and OX402 memory T cells from HVs (A) and Allo HSCT recipients (B) were stimulated with
aCD3/28 or aCD3/28/OX40 for 12 hours, washed, cultured in medium for 4 days, and then restimulated with aCD3/28 for 6 hours. The di-
vision profile and cytokine production of the cells were then analyzed. (A) The dot plots are representative of 3 HVs. (B) The dot plots are rep-
resentative of two Allo HSCT recipients.
278 T. Shindo et al.OX401 memory cells. Interestingly, both OX401
memory and OX402 memory cells are positive for
IL-7Ra, and IL-7 stimulation results in similar levels
of STAT5 phosphorylation in both cell subsets. The
selective action of IL-7 on OX401 memory cells im-
plies that IL-7 in OX401 memory cells invokes a set
of transcription factors that is not induced by IL-7 in
OX402 memory cells. In other words, the expression
of OX40 in CD41 T cells may guide IL-7 toward its
cellular target. Although IL-7 is known to enhance T
Figure 7. Allo HSCT recipients with cGVHD have much higher
frequencies of IL-2-producing CD41OX401 T cells than Allo
HSCT recipients without cGVHD. Peripheral blood mononuclear
cells from Allo HSCT recipients were stimulated with PMA/Iono
stimulation for 4 hours in the continuous presence of BFA. (A) A rep-
resentative dot plot of surface OX40 and intracellular IL-2 is shown.
The gates were set at the CD41 lymphocytes. (B) Comparison of the
frequencies of OX40-expressing and IL-2-producing OX401 cells in
the CD41T cell populations of Allo HSCT recipients with (n5 15)
and without (n 5 10) cGVHD is shown.cell reconstitution after AlloHSCT [51,52], several re-
ports have raised the concern that exogenous IL-7 ad-
ministration to Allo HSCT recipients exacerbates
GVHD [53,54]. In addition, endogenous IL-7, which
is produced by the stromal cells in bone marrow, thy-
mus, and lymph nodes [55], is suspected to ameliorate
not only GVHD after Allo HSCT but also the rejec-
tion reaction after solid organ transplantation
[56,57]. In any case, the significance of the increased
sensitivity of OX401 memory cells to IL-7 will con-
tinue to be investigated.
We found thatCD41OX401Tcells have amarked
potential for proliferation and differentiation in vitro,
especially if TCR ligation and costimulation through
OX40 are provided simultaneously. Although we pre-
viously reported that OX40-mediated signaling on its
own activates nuclear factor kappa B through a TNF
receptor-associated factor-mediated pathway [58,59],
sequential delivery of OX40-mediated signaling after
the removal of TCR ligation did not result in cell
growth or differentiation at all. Endl et al [60] have
suggested that the expression of OX40 in vivo seems
to be restricted to CD41 T cells that are exposed to
high-affinity ligands. In addition, it takes at least
a day for CD41OX402 memory T cells to express
OX40 after antigenic stimulation in vitro. As activated
dendritic cells have been shown to express OX40L
[17,61], CD41OX401T cells that enter the secondary
lymphoid organs would have great advantage over
CD41OX402T cells in their clonal expansion and dif-
ferentiation into effector memory T cells after their
first encounters with APCs. In this study, there were
some differences between CD41OX401 T cells of
Allo HSCT recipients and those of HVs. Although
CD41OX401 T cells of Allo HSCT recipients explo-
sively proliferated and functionally differentiated in re-
sponse to aCD3/28/OX40 stimulation, those of HVs
did not (Figures 5A, the upper half of Figure 5C, and
Figure 6). As the lymphopenic conditions seen in the
Allo HSCT recipients promote the production of
IL-7 [62], CD41OX401 T cells from Allo HSCT re-
cipients might already have more of the IL-7-mediated
signal than the CD41OX401T cells fromHVs before
sampling. In addition, it is interesting that OX401
memory cells of some patients differentiated mainly
into Th1-typed cells, whereas others showed Th2-
biased differentiation.
Although the CD41OX401Tcell population con-
tains cells that produce a large amount of IL-2, it also
includes cells without IL-2-producing capacity. T cells
with IL-2-producing capacity have been reported to
actively proliferate and differentiate in vivo [63,64].
These results are meaningful when taken together
with our finding that the frequency of IL-2-producing
CD41OX401 T cells is much higher in Allo HSCT
recipients with cGVHD than those without it. Recent
studies on murine GVHD models have suggested
Many Advantages in Growth of CD41OX401 T Cells 279that donor-derived alloreactive T cells are activated in
secondary lymphoid tissues before they migrate into
target organs and cause tissue damage [65,66]. Al-
though further studies are needed, the findings that
CD41OX401 memory T cells with IL-2-producing
capacity have increased sensitivity to IL-7 and can
home to lymphoid organs and easily expand and differ-
entiate into effector cells in response to antigenic stim-
ulation, suggesting that they might have a role to play
in the process of development and maintenance of
cGVHD.
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